IDL Diagnostics (ex-AroCell AB) - Better Than Its Reputation

Redeye’s updated report. after Q2.

They slightly lowered their '23 and '24 forecasts, but are not making changes to the company’s long-term projections. They predict positive cash flow for 2025. The analyst also doesn’t see an issue with capital adequacy.

Below are Redeye’s adjusted forecasts for 2023 and '24 regarding depreciation and amortization.

The stock has mostly been heading downhill during the year and would certainly be attractively cheap.
Having learned from a couple of bad experiences, I am trying to avoid jumping on board too early, so for now, I will continue to monitor the progress of the turnaround.

6 Likes